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Abstract
Background: Age-related degeneration(AMD) and asthma are both diseases that are related to the activation of the
complement system. The association between AMD and asthma has been debated in previous studies. The authors
investigated the relationship between AMD and asthma systemically.
Principal Findings: The epidemiological study showed that asthma was related to choroidal neovascularization(CNV)
subtype(OR=1.721, P=0.023). However, the meta-analysis showed there was no association between AMD and asthma. In
an animal model, we found more fluoresce in leakage of CNV lesions by FA analysis and more angiogenesis by histological
analysis in rats with asthma. Western blot demonstrated an elevated level of C3a-chain, C3a’-chain and VEGF. After
compstatin was intravitreally injected, CNV leakage decreased according to FA analysis, with the level of C3 and VEGF
protein decreasing at the same time.
Significance: This study first investigated the relationship between AMD and asthma systematically, and it was found that
asthma could be a risk factor for the development of AMD. The study may provide a better understanding of the disease,
which may advance the potential for screening asthma patients in clinical practice.
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Introduction
Age-related macular degeneration (AMD), the most common
cause of irreversible blindness in the elderly population in many
countries, affects the macular area ofthe retina [1,2]. There are two
major clinical phenotypes of AMD–a nonexudative type(dry AMD)
and an exudative type (wet AMD) [3]. During the development of
AMD, choroidal neovascularization (CNV), or the development of
new pathological blood vessels, is the major cause of vision loss [4].
The pathogenesis of CNV is poorly understood. As a complex
disease, multiple environmental and genetic risk factors for CNV
have been identified [5–9]. Studies recently indicated that inflam-
mation, especially the alternative complement pathway, plays a
fundamental role in the development of CNV [10]. Additionally,
genetic evidence has identified variations in multiple genes involved
in the complement cascade, including complement factor 3 (C3),
complementfactorH(CFH),complementfactorBandcomplement
factor 2 (C2), associated with AMD [11–13]. Apart from the
complement system,otherangiogenic stimulihavebeenreported to
take part in the development of CNV, with the most important one
being vascular endothelial growth factor [14].
Bronchial asthma (BA) is an inflammatory disorder of the
airways characterized by airway hyper responsiveness and
reversible airway obstruction [15]. Like CNV, BA is a multifunc-
tional disorder with both environmental and genetic factors
contributing to its development. Recent studies reveal that the
complement system plays a crucial role in the development of
immunological responses in BA by initiating and/or amplifying
airway inflammation [16,17]. Variations of genes in the comple-
ment system have been shown to confer susceptibility to BA,
including complement factor 3(C3) and complement factor 4(C4).
Because the mechanisms of development for both CNV and
asthma are alike, we hypothesize that there is a relationship
between these two diseases. During the past decade, several
population-based studies reported that a history of asthma is
associated with a high risk of developing CNV. However, other
studies have also shown no association between asthma and CNV.
Therefore, the association between these two diseases remains
unknown.
In this study, we examined the cross-sectional relationship
between asthma and CNV in a population-based sample of the
mongoloid race in China. We then carried out a meta-analysis on
all currently available studies to estimate the strength of a history
of asthma being associated with CNV. Furthermore, a rat model
of CNV induced by laser was developed in rats with asthma to
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e35415investigate whether asthma is a risk factor for CNV and the
potential mechanism of association.
Results
An Epidemiological Study Demonstrating the Association
between CNV and Asthma
An epidemiological study was performed to determine if there is
a correlation between a history of asthma and CNV. Of the 462
AMD patients, asthma was present in 47(10.17%) patients,
whereas out of the 502 healthy controls, 31(6.18%) had asthma.
The association of asthma and CNV was statistically significant
(OR=1.721, P=0.023). As a result, asthma was found to be
related to CNV (Tab.1).
Meta-analysis Showing no Association between CNV and
Asthma
To obtain more information about the results of other
epidemiological studies, a meta-analysis was performed. Seven
epidemiological studies were identified that provided information
regarding the potential association of CNV and asthma. All of the
studies analyzed were written in English [18–23]. There were two
articles that included multiple studies [20,23], and we treated each
study separately. 4054 CNV cases and 109006 healthy controls,
for a total of 113060 subjects, were included in the study. When
we pooled all seven studies into this meta-analysis, we found no
significant association between the risk of AMD and asthma (OR:
0.98; 95% CI:0.82–1.06) (Fig. 1). We also performed Egger’s test
to check whether there was publication bias, and it confirmed that
in the dominant model, there was an absence of publication bias
(Fig. S1).
An Asthma Rat Model Shows More Fluorescein Leakage
from Laser Induced Choroidal Neovascularization Lesions
on FA Analysis and More Neovascularization on
Histological Analysis than in Rats without Asthma
The results of our epidemiological study and meta-analysis
were inconclusive. Therefore, an animal model was established to
provide further analysis. According to the epidemiological study
we performed, CNV was related to asthma. Thus, a CNV model
was developed in rats with asthma and in rats without asthma as
a control. CNV leakage in rats with and without asthma was
assessed by fluorescein angiography to see whether rats with
asthma were more likely to develop CNV. Using FA performed
on day 7 after laser-induced CNV, very few patches of hyper-
fluorescence leakage were observed at the lesion site of rats
without asthma, but leakage could be seen in rats with asthma,
and there was a significant difference (P=0.001). The leakage
distribution at day 14 increased when compared to day 7. There
were a total of 33 CNVs in five rats with asthma, while the
number of CNV patches in the groups without asthma was
16(P=0.002) (Fig. 2).
Two weeks after laser photocoagulation, histopathology per-
formed on hematoxylin and eosin stains obtained from paraffin
cross-sections confirmed that there was increased invasion in the
retina around the laser scars in rats with asthma compared to rats
without asthma. There were significant differences in the B/C
ratio between the groups with asthma and the control (P=0.001)
(Fig. 3).
Meta-analysis Demonstrating an Association between C3
and CNV
The relationship between C3 and CNV has been previously
reported. However, to obtain a systematic review, a meta-analysis
of C3 R102G and CNV was performed. 16 genetic epidemiolog-
ical studies were previously preformed to analyze the association of
CNV and the C3 R102G polymorphism (4 studies were over-
lapped) [7,24–26], and all of them were written in English. There
were 14 articles published regarding the association between
R102G and AMD risk. Because 3 studies were overlapping, we
selected the articles with the largest sample size. There were
2 articles that included more than one study [24,25], and we
treated them as separate studies.
The genotype effects for GC and GG versus CC genotypes were
1.459 (95% CI: 1.278, 1.667) and 1.471 (95% CI: 1.016, 2.130),
respectively. This meant that patients who had GG and GC
genotypes were roughly 1.5 times more likely to have AMD than
patients with the CC genotype. These results suggested a
codominant genetic model in which C3 R102G polymorphism
plays an important role in the pathogenesis of AMD (Fig. 4).
Increased Expression of C3 and VEGF Could Affect the
Development of CNV in Rats with Asthma
We next investigated the possible mechanism why rats with
asthma developed more CNV than rats without asthma. As
mentioned above, C3 and VEGF play fundamental roles in the
development of both CNV and asthma. Western blot analysis of
C3 and VEGF was performed, with b-actin serving as an
internal loading control. We found an increase in the levels of
the C3 split products (113 kDa for C3a-chain and 106 kDa for
C3a’-chain) and VEGF (51 kDa) in rats with asthma compared
to rats without asthma. C3a-chain levels were significantly
increased by 2.59 fold (P=0.006), with C3a’-chain levels
increasing 3.00 fold (P=0.023) and VEGF level increasing 2.87
fold (P=0.031) (Fig. 5).
Inhibitory Effect of Compstatin on CNV-associated Down
Regulation of C3 and VEGF
Given that the result has shown that CNV growth is associated
with C3 and VEGF, either of the following scenarios is plausible:
1) elevated C3 levels induce an increase in VEGF, 2) elevated
VEGF levels induce an increase in C3, or 3) C3 and VEGF levels
are elevated independently.
To gain further insight into the relationship between VEGF and
C3 and their effects on CNV in asthma, we investigated the use of
compstatin to test the effect of C3 activation in the retina. 7 days
after intravitreal injection of compstatin, fluorescein angiography
was performed and CNV leakage was analyzed. The number of
CNV patches in the rats receiving intravitreal injection was 10
compared with 33 CNV patches in rats that had not received
intravitreal injection. Pathologic leakage was significantly reduced
after treatment with compstatin (P=0.03) (Fig. 6). Western blot
analysis revealed a significant down regulation in the levels of C3a-
Table 1. The epidemiological study among Chinese people.
Asthma
(%)
Non-
asthma(%) x2 P OR 95%CI
CNV 47 (10.17) 415 (89.83) 5.171 0.023* 1.721 (1.073,2.759)
Non-CNV 31 (6.18) 471 (93.82)
Patients with a history of asthma that developed CNV compared with controls
in our epidemiological study.
doi:10.1371/journal.pone.0035415.t001
An Epidemiological Study and an Animal Model Experiment
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and 1.82 (P=0.044) fold, respectively, in RPE/choroid samples
from CNV rats (Fig. 5). Thus, having asthma may provide a
source of C3, raising the probability that locally produced C3 may
precipitate VEGF release and CNV development [10].
Discussion
Our epidemiological study demonstrated that CNV was related
to asthma. However, the meta-analysis showed a summary OR of
0.98(95%CI: 0.82–1. 06), which was contrary to our results.
Further experiments found that in an animal model, rats with
asthma had earlier and more extensive neovascularization
compared with rats without asthma and C3 and VEGF may
have played a fundamental role in this difference.
The association between CNV and asthma was controversial in
previous studies. In our epidemiological study, asthma was
associated with CNV with a 95% CI of 1.721. Among relevant
studies searched, Inbal Goldshtein found a history of asthma was a
risk factor for CNV. However, Jie Jin Wang and Ronald Klein
Figure 1. Forest plot showing the results of our meta-analysis. Each study is shown by the point estimate of the OR(the size of the square is
proportional to the weight of each study) and 95% CI for the OR(extending lines).
doi:10.1371/journal.pone.0035415.g001
An Epidemiological Study and an Animal Model Experiment
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integrating the accumulating evidence, our meta-analysis demon-
strated that asthma was not associated with CNV. This result was
convinced because no potential publication bias was found. Thus,
the results of our epidemiological study and meta-analysis were not
consistent. There are several possible explanations for the
inconsistency we found. First, there were a limited number of
publications available, which included a total of only 7 studies.
Therefore, the small sample size used for our meta-analysis could
be a reason for the discrepancy. Second, because different studies
were carried out in different regions and in different ethnic groups
(Imran A. Bhutto in USA, Andrew Lotery in UK, Inbal
Goldshtein in Israel, Jie Jin Wang in Australia and Ronald Klein
in USA), there could be significant differences in both the
environment and inheritance of genes that could potentially bias
the results. Different regions and ethnic groups also have
variability in the frequency and severity of asthma attacks, which
could lead to deviations. Third, according to our epidemiological
study, asthma was related to CNV but not to dry AMD. However,
in the studies we searched for our meta-analysis, the subgroups
CNV and dry AMD were not distinguished. The absence of
subgroups, therefore, may be a factor in why different results were
obtained.
Our animal model study demonstrated that asthma is a risk
factor for the development of CNV, which we speculated could be
a consequence of systemic inflammation associated with asthma.
Systemic inflammation induced by asthma and the ocular
inflammation that results may explain the relationship between
CNV and asthma. An inflammatory response is involved in the
development of CNV in both rats and humans [10]. There is
strong evidence suggesting that in the pathogenesis of choroidal
angiogenesis both systemic and ocular inflammation are involved
Figure 2. CNV leakage on FA. Angiographic analysis of CNV leakage 7 and 14 days after laser photocoagulation in 5rats with asthma and the
control group 5 rats. Rats with asthma developed more CNV leakage on both day 7 (A, B) and day 14 than the rats in the control group (C, D).
doi:10.1371/journal.pone.0035415.g002
Figure 3. H&E staining of representative areas of CNV. H&E staining of representative areas of CNV at the sites of laser-induced lesions in 5 rats
with asthma (A) and the 5 control group (B).Eyes were removed 14 days after laser photocoagulation. Note the presence of laser-induced CNV in each
group.
doi:10.1371/journal.pone.0035415.g003
An Epidemiological Study and an Animal Model Experiment
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allergens are known to drive allergic airway inflammation and
activation of the inflammatory corpuscle resulting in systemic
cytokine release.
Activation of the AP has been well documented in the
development of CNV. As a point of convergence of the AP, C3
plays an important role in the control of the innate immune system
and the inflammatory reaction that has been suggested to
contribute in the pathogenesis of CNV. In patients with asthma,
increased levels of serum C3 have been described [17]. As a result
of systemic C3 elevation, local C3 levels are elevated accordingly
resulting in local activation of the complement pathway.
Our study showed higher levels of C3 and VEGF in rats with
asthma compared to rats without asthma. To determine whether
the accumulation of C3 induced VEGF or if the opposite is true, a
C3 inhibitor–compstatin was used. We found that C3 and VEGF
protein levels decreased at the same time. According to Puran S.
Bora, C3 activity is critical for the formation and deposition of the
terminal membrane attack complex (MAC) on RPE and choroid
cells, which leads to transient changes in the permeability of cell
membrane. Changes in the permeability of the cell membrane
lead to induction and release of VEGF, which eventually leads to
the development of CNV [3] (Fig. 7).
Compstatin is a potent inhibitor of the complement system
which inhibits cleavage of complement protein C3 [27]. Although
it was tested to be inactive against C3 from lower mammals in a
Surface Plasmon Resonance (SPR) chips measurement experiment
[28], we believe in its functions intravitreally, still. As SPR only
analyzes the binding process, its affinity for compstatin could be
affected in vivo by other small molecules. And because of its
specificity of the detection is not high enough, further studies such
as IP are needed to test their result. In vivo studies are needed, too.
According to our study, asthma is a risk factor in the
development of CNV because people with asthma are more likely
to have CNV. This information could potentially lead to earlier
screening for CNV in patients with asthma.
In conclusion, CNV is associated with asthma in our
epidemiological study. However, previous studies show conflicting
conclusions. We also found that asthma may affect the develop-
ment of CNV, by increasing the protein levels of C3 and VEGF in
the RPE/choroid layers, as observed in a rat model of allergic
asthma. This study was the first to systematically investigate the
Figure 4. Meta-analysis of C3 R102G and AMD. Forest plot for meta-analysis of association between R102G and AMD risk. Each study is shown
by the point estimate of the odds ratio (OR)(the size of the square is proportional to the weight of each study) and 95% confidence interval(CI) for the
OR(extending lines).
doi:10.1371/journal.pone.0035415.g004
An Epidemiological Study and an Animal Model Experiment
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understanding of the disease. This knowledge may help to advance
the potential for screening among asthma patients in clinical
practice.
Materials and Methods
Epidemiological Study
17 hospitals located in 9 different provinces in China enrolled
545 patients and 509 healthy controls from May 2010 to March
Figure 5. Western blot of C3 and VEGF. Western blot showing C3a’-chain, C3a-chain and VEGF expression in the RPE/choroid layer of rats
without asthma, rats with asthma and rats with asthma treated with compstatin 14 days after laser photocoagulation. This experiment was repeated
three times.
doi:10.1371/journal.pone.0035415.g005
Figure 6. CNV leakage on FA after compstatin injection intravitreally. Angiographic analysis of CNV leakage 7 days after intravitreal
compstatin injection. The pathologic leakage in rats with asthma was reduced after treatment.
doi:10.1371/journal.pone.0035415.g006
An Epidemiological Study and an Animal Model Experiment
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according to Fluorescein angiography (FFA) and/or Optical
Coherence Tomography (OCT) were included as long as they
had no other retinal diseases. Patients with pathological myopia,
macular dystrophy, central serous chorioretinopathy, retinal vein
occlusion, diabetic retinopathy or uveitis were excluded. All
healthy patients were examined by FA and/or OCT to exclude
CNV. A history of asthma was surveyed and the diagnoses were
made by respiration experts according the Global Initiative for
Asthma Guidelines 2007.
Meta-analysis
Publication search. Meta-analysis was performed as previ-
ously described [29]. Relevant studies were found by searching the
following keywords: ‘‘asthma’’ and ‘‘AMD’’ or ‘‘CNV’’ in Pub
Med, Medline and Web of Science databases (updated to Oct 18,
2011). All of the selected studies were retrieved, with their
references checked for other relevant publications as well. No
minimum number of patients was required for meta-analysis.
Different sub-studies in the same article were treated as separate
studies. In this meta-analysis, we selected only those studies
published in English and only when the full text articles were
available. For each paper, we extracted the following information
into a table: first author, year of publication, number of cases and
controls, and crude odds ratio (OR). Two authors (Yaoyao Sun
and Peng Zhou) read the identified articles carefully and assessed
them independently. For any discrepancies in their eligibility, they
were adjudicated by Xiaoxin Li.
Statistical methods. The OR with 95% confidence intervals
(CI) was calculated to evaluate the association strength between a
history of asthma and CNV risk. Both fixed-effects (the Mantel-
Hzenszel method) and random-effects (Der Simonian and Laird
method) models were chosen. Cochran’s Q statistic was used for
determining the statistical significance of heterogeneity. If the p-
value was less than 0.10, we selected the random-effects model
otherwise the fixed-effects model was used. We used forest plots to
describe the results from separate studies as well as for a summary
containing all of the results. We used Egger’s tests to test the
potential for publication bias, and if P,0.05, the publication bias
was considered to be statistically significant. Forest plots were
produced to graphically present significant findings. Funnel plots
were used to explore the potential for publication bias (PRISMA
checklist) [30].
Because few studies investigating the association between C3
SNPs and asthma were found, we analyzed only the association
between C3 SNPs R102G polymorphisms and AMD because this
SNP has been the most commonly studied one. In order to obtain
additional results, the following four different types of OR were
calculated: (1) CG versus CC genotype, (2) GG versus CC
genotype, (3) CG plus GG versus CC genotype (which was the
dominant model) and (4) GG versus CG plus CC genotype (which
was the recessive model).
All of the statistical calculations were conducted using Stata/Se
version 11.0 software (Stata Corporation, College Station, TX).
Animals
Specific, pathogen-free female Brown Norway (BN) rats
weighing 150610 g were purchased from the Laboratory Animal
Center, Peking University People’s Hospital. Animal care and
experiments were conducted under institutional guidelines and
food and tap water were given ad libitum.
Establishment of an asthmatic rat model. On days 0 and
5, 10 rats in the asthma group were actively sensitized by
intraperitoneal (i.p.) injection of 1mg ovalbumin (OVA, Sigma-
Aldrich, St. Louis, MO, USA) emulsified with 40 mg Imject Alum
(Pierce, Rockford, IL USA) in a total volume of 1ml. In order to
elicit an airway allergic response, these rats were placed in a
chamber made of plastic and challenged with an OVA aerosol
(1% (w/v) in 0.9% NaCl) nebulized by an ultrasonic nebulizer
(PARI BOY, PARI GmbH, Sternberg, Germany) twice a day for
1hour from days 6 to 14.10 rats in the negative control group were
sham immunized with 0.9% NaCl and then challenged with an
aerosol of 0.9% NaCl at the same frequency as the asthma group
[31,32]. HE staining of lung in asthma was carried out (Fig. S2),
and the status asthmaticus in asthma rats was recorded by video
(Video S1, Video S2).
Induction of CNV. CNV was induced by laser photocoag-
ulation (532 nm, 150 mW, 100 ms, 100 mm).
(Coherent 130SL, Coherent, Santa Clara, CA, USA) performed
on day 15 when the asthma model was thought to have already
been established. 8 lesions were made on one eye of each rat, and
the other eye was used as the control.
Intravitreally injection of compstatin. To test the effect of
suppressing complement activation in the retina of rats with
asthma, 20 mg compstatin, a small cyclic synthetic peptide (Tocris
Bioscience, Ellisville, Missouri, USA), was intravitreally injected
into 5 rats 7 days after CNV was induced. Compstatin was
dissolved in 1ml of 0.9% NaCl solution per 100 mg, filtered and
intravitreally injected with a micro injector while the rats were
anesthetized with 0.5 ml 10% chloral hydrate injected i.p.
The Measurement of CNV
Fluorescein angiography. Fluorescein angiography (FA)
was performed on day of 7 and 14 after laser photocoagulation
using a digital imaging system (TOPCON 50DX, Topcon, Tokyo,
Japan) as described previously [33]. 0.2 ml of 5% fluorescein was
given by i.p. after the rats were anaesthetized using the method
described above and FA was done with pupil dilation. Both early-
phase (1 minute after injection) and late-phase (5 minutes after
injection) fundus angiograms were analyzed [34]. Fluorescein
angiograms were evaluated quantitatively and the leakage area for
each lesion was measured using ImageJ software, a custom
programmed macro provided by the National Institutes of Health
(NIH).
Histological analysis and CNV size measurement. 14
days after laser photocoagulation, the eyeballs of the experimental
eye were removed and were fixed in eyeball fixing solution for
24 hours at room temperature. After removal of the anterior
segments, the posterior eyecups were embedded in paraffin.
Sagittal sections of 6mm were cut through the center of the eye at
the site of laser photocoagulation. The sections were stained by
hematoxylin and eosin and assessed by light microscopy (LEICA
DFC 300FX, Leica, Solms, Germany). A computer-assisted image
analysis system was used to estimate neovascularization based on
the B/C ratio (B stands for the thickness between the bottom of the
pigmented choroidal layer and the top of the neovascular
membrane, while C stands for the thickness of the intact-
pigmented choroid next to the lesion [35]. Measurements were
performed on four sections from each laser photocoagulation site.
Western Blot
Fourteen days after laser photocoagulation, we removed the
experimental eyeballs and extracted protein. Total protein was
extracted from the pooled RPE/choroid layers and protein
concentration was measured using the Bio-Rad assay kit (Bio-
Rad, Hercules, CA, USA). Equal amounts of protein (30–60 mg)
were resolved on 12% (for C3 antibody) or 6% (for VEGF and b-
actin antibodies) Tris-HCl polyacrylamide gels and then trans-
An Epidemiological Study and an Animal Model Experiment
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USA). After blocking, membranes were incubated with specific
antibodies for C3 (Santa Cruz, CA, USA), VEGF (Abcam,
Cambridge, MA, USA) and b-actin (Abcam, Cambridge, MA,
USA). After incubation with peroxidase-conjugated goat anti-
rabbit or anti-mouse secondary antibodies (ZSGB-Bio, Beijing,
China), protein bands were visualized by chemiluminescence
(Pierce, Rockford, IL, USA). This experiment was repeated three
times, and similar results were obtained each time [36,37].
Statistical Analysis
All of the experiments were repeated three times and the data
were presented as mean6SEM. Data were analyzed using
Student’s T test. p,0.05 was considered statistically significant.
All data analyses were performed with SPSS 17.0 (Chicago, IL,
USA).
Supporting Information
Figure S1 Publication bias of the meta-analysis. The
Begg’s funnel plot of studies included in the meta-analysis between
asthma and AMD(A) and between C3 R102G and AMD(domi-
nant model,B). The vertical axis represents log[OR] and the
horizontal axis means the standard error of log[OR]. Horizontal
line and sloping lines in funnel plot represent random effect
summary OR and expected 95%CI for a given standard error,
respectively. Area of each circle represents the contribution of each
study to the pooled OR.
(TIF)
Figure S2 HE stainings of lung in asthma group and
control group. Remarkble infiltration of inflammatory cells
(including eosinophils and neutrophils) around the bronchioles
with the destruction of epithelium, accumulation of inflammatory
debris could be seen in asthma rats(A) but not in control rats(B).
(TIF)
Video S1 showed the status asthmaticus in asthma rats.
(WMV)
Video S2 showed the normal performance in the control
group.
(WMV)
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